Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 229 full-time employees. The firm develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. The company is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción GERN?
El precio actual de GERN es de $1.33, ha increased un 0.98% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Geron Corp?
Geron Corp pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Geron Corp?
La capitalización bursátil actual de Geron Corp es $850.4M
¿Es Geron Corp una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 10 analistas han realizado calificaciones de análisis para Geron Corp, incluyendo 5 fuerte compra, 6 compra, 3 mantener, 1 venta, y 5 fuerte venta
